Previous studies have reported that Nampt mRNA is decreased in the liver of human subjects with non-alcoholic fatty liver disease, and Nampt has been shown to protect hepatocytes by increasing SIRT1 activity [36,37]. Here, NAMPT is linked to metabolic dysfunction-associated steatotic liver disease.